https://www.selleckchem.com/pr....oducts/Amprenavir-(A
98-114.29; AUC 91.09-121.86; C 94.08-111.9. Mean serum CT-P17 concentrations, secondary pharmacokinetic parameters and numbers of subjects with antidrug antibodies (ADAs) or neutralising ADAs were comparable between groups. AUC , AUC and C were numerically lower for ADA-positive than for ADA-negative subjects (both groups); pharmacokinetic equivalence was also demonstrated among ADA-positive subjects. CT-P17 AI and CT-P17 PFS were well tolerated, with comparable overall safety profiles. CT-P17 AI and CT-P17 PFS were pha
Like
Comment
Share
